Pilatus announced raising $14 million to fund the first-in-human clinical study of its anti-CD36 monoclonal antibody (mAb).1
The news was reported as a top story by FirstWord Pharma, referencing Business Wire.1
Publication date:
December 15, 2025.1
Sources:
1. https://firstwordpharma.com/story/6745446